NeuroMetrix, Inc.: Nasdaq/NYSE listing notice — Nasdaq warns NeuroMetrix (NURO) of delisting for bid price below $1.00; 180-day cure period

NeuroMetrix, Inc.

Received Nasdaq notice on Aug 8, 2023 for failure to meet minimum $1.00 bid price per share for 30 consecutive business days.
Has 180 calendar days, until Feb 5, 2024, to regain compliance by closing at $1.00 or more for ten consecutive business days.
If not compliant by deadline, Nasdaq may delist; company can appeal or seek an additional 180-day grace period if eligible.
Stock remains listed on The Nasdaq Capital Market; the notice has no immediate effect on trading.
Company intends to actively monitor its bid price to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

NeuroMetrix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

August 8, 2023, NeuroMetrix, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notice states that pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company will be afforded 180 calendar days, or until February 5, 2024, to regain compliance with the minimum bid price require

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001628280-23-029115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.